UA125463C2 - ЗАСТОСУВАННЯ МОДУЛЯТОРІВ GABA<sub>A</sub>-РЕЦЕПТОРА ДЛЯ ЛІКУВАННЯ СВЕРБЕЖУ - Google Patents
ЗАСТОСУВАННЯ МОДУЛЯТОРІВ GABA<sub>A</sub>-РЕЦЕПТОРА ДЛЯ ЛІКУВАННЯ СВЕРБЕЖУ Download PDFInfo
- Publication number
- UA125463C2 UA125463C2 UAA201808382A UAA201808382A UA125463C2 UA 125463 C2 UA125463 C2 UA 125463C2 UA A201808382 A UAA201808382 A UA A201808382A UA A201808382 A UAA201808382 A UA A201808382A UA 125463 C2 UA125463 C2 UA 125463C2
- Authority
- UA
- Ukraine
- Prior art keywords
- unsubstituted
- substituted
- compound
- mice
- shi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16153035 | 2016-01-27 | ||
| EP16178824 | 2016-07-11 | ||
| PCT/EP2017/051866 WO2017129801A1 (en) | 2016-01-27 | 2017-01-27 | Use of gabaa receptor modulators for treatment of itch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA125463C2 true UA125463C2 (uk) | 2022-03-16 |
Family
ID=57890845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201808382A UA125463C2 (uk) | 2016-01-27 | 2017-01-27 | ЗАСТОСУВАННЯ МОДУЛЯТОРІВ GABA<sub>A</sub>-РЕЦЕПТОРА ДЛЯ ЛІКУВАННЯ СВЕРБЕЖУ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10786513B2 (enExample) |
| EP (1) | EP3407886A1 (enExample) |
| JP (2) | JP7115746B2 (enExample) |
| KR (1) | KR102482200B1 (enExample) |
| CN (1) | CN108697694B (enExample) |
| AU (1) | AU2017213154B2 (enExample) |
| BR (1) | BR112018015386A2 (enExample) |
| CA (2) | CA3012791C (enExample) |
| CL (1) | CL2018002023A1 (enExample) |
| IL (1) | IL260775B (enExample) |
| MX (1) | MX388862B (enExample) |
| SG (1) | SG11201806393QA (enExample) |
| UA (1) | UA125463C2 (enExample) |
| WO (1) | WO2017129801A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018015386A2 (pt) | 2016-01-27 | 2019-03-19 | Universität Zürich | uso de moduladores de receptor gabaa para tratamento de prurido |
| CN112384513A (zh) | 2018-04-18 | 2021-02-19 | 纽罗塞克医疗公司 | Gabaa正变构调节剂化合物、其制备方法和用途 |
| WO2019226820A1 (en) * | 2018-05-22 | 2019-11-28 | Neurocycle Therapeutics, Inc. | Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis |
| HUE060943T2 (hu) * | 2018-09-13 | 2023-04-28 | Saniona As | A gaba A receptor ligandum |
| WO2020191047A1 (en) * | 2019-03-18 | 2020-09-24 | Neurocycle Therapeutics, Inc. | Use of gabaa receptor modulators for treatment of pain |
| CN110004118B (zh) * | 2019-03-29 | 2023-03-28 | 中国科学院武汉物理与数学研究所 | 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用 |
| CA3155618A1 (en) * | 2019-10-23 | 2021-04-29 | Jed Hubbs | Treatment of epileptic conditions with gabaa receptor modulators |
| US12233070B2 (en) * | 2020-06-30 | 2025-02-25 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1024526A (en) | 1911-07-25 | 1912-04-30 | George R Schweikert | Chair. |
| EP0915875B1 (en) * | 1996-07-25 | 2003-04-09 | MERCK SHARP & DOHME LTD. | Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
| FR2767692B1 (fr) * | 1997-09-01 | 2000-03-03 | Oreal | Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB9903119D0 (en) * | 1999-02-11 | 1999-04-07 | Merck Sharp & Dohme | Therapeutic agents |
| AU1253002A (en) | 2000-11-10 | 2002-05-21 | Merck Sharp & Dohme | Imidazo-triazine derivatives as ligands for gaba receptors |
| GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| WO2003082832A2 (en) | 2002-03-28 | 2003-10-09 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| JP2004170323A (ja) * | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| WO2005030773A1 (ja) * | 2003-09-26 | 2005-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピラゾロピリミジン誘導体 |
| WO2005108401A1 (en) * | 2004-04-29 | 2005-11-17 | Dov Pharmaceutical, Inc. | 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones |
| WO2006061428A2 (en) * | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| KR20060087386A (ko) * | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| TW200823215A (en) | 2006-08-04 | 2008-06-01 | Merz Pharma Gmbh & Amp Co Kgaa | Pyrazolopyrimidines, a process for their preparation and the use as a medicine |
| GEP20125658B (en) | 2006-11-22 | 2012-10-10 | Incyte Corp | Imidazotriazines and imidazo pyrimidines as kinase inhibitors |
| WO2009021957A2 (en) * | 2007-08-14 | 2009-02-19 | Novartis Ag | Tricyclic heterocyclic compounds as gaba a modulators |
| SI2300455T1 (sl) | 2008-05-21 | 2017-12-29 | Incyte Holdings Corporation | Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| EP2456311A4 (en) | 2009-07-24 | 2013-01-23 | Concert Pharmaceuticals Inc | SUBSTITUTED IMIDASOTRIAZINES |
| US8809541B2 (en) | 2010-08-25 | 2014-08-19 | Neopharm Co., Ltd. | Heterocyclic compound, and composition for treating inflammatory diseases using same |
| US20130331394A1 (en) * | 2012-06-11 | 2013-12-12 | The Mclean Hospital Corporation | Treating schizophrenia |
| MX362181B (es) * | 2013-02-19 | 2019-01-08 | Ono Pharmaceutical Co | Compuesto inhibidor de cinasa del receptor de tropomiosina (trk). |
| WO2015072853A1 (en) * | 2013-11-13 | 2015-05-21 | Rjg Developments B.V. | Treatment of herpes virus infection outbreaks |
| GB201321732D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| WO2016154031A1 (en) | 2015-03-20 | 2016-09-29 | Uwm Research Foundation, Inc. | Gabaergic ligands and their uses |
| BR112018015386A2 (pt) | 2016-01-27 | 2019-03-19 | Universität Zürich | uso de moduladores de receptor gabaa para tratamento de prurido |
-
2017
- 2017-01-27 BR BR112018015386-9A patent/BR112018015386A2/pt not_active IP Right Cessation
- 2017-01-27 AU AU2017213154A patent/AU2017213154B2/en not_active Expired - Fee Related
- 2017-01-27 EP EP17701549.2A patent/EP3407886A1/en active Pending
- 2017-01-27 WO PCT/EP2017/051866 patent/WO2017129801A1/en not_active Ceased
- 2017-01-27 UA UAA201808382A patent/UA125463C2/uk unknown
- 2017-01-27 CN CN201780008490.1A patent/CN108697694B/zh not_active Expired - Fee Related
- 2017-01-27 KR KR1020187022974A patent/KR102482200B1/ko active Active
- 2017-01-27 MX MX2018009252A patent/MX388862B/es unknown
- 2017-01-27 CA CA3012791A patent/CA3012791C/en active Active
- 2017-01-27 JP JP2018539149A patent/JP7115746B2/ja active Active
- 2017-01-27 CA CA3222584A patent/CA3222584A1/en active Pending
- 2017-01-27 SG SG11201806393QA patent/SG11201806393QA/en unknown
-
2018
- 2018-07-25 IL IL260775A patent/IL260775B/en unknown
- 2018-07-25 US US16/045,193 patent/US10786513B2/en active Active
- 2018-07-26 CL CL2018002023A patent/CL2018002023A1/es unknown
-
2020
- 2020-08-14 US US16/994,146 patent/US11529359B2/en active Active
-
2022
- 2022-04-04 JP JP2022062494A patent/JP2022088620A/ja active Pending
- 2022-09-01 US US17/901,356 patent/US12433898B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180118623A (ko) | 2018-10-31 |
| BR112018015386A2 (pt) | 2019-03-19 |
| KR102482200B1 (ko) | 2022-12-27 |
| CA3012791C (en) | 2024-01-23 |
| CA3012791A1 (en) | 2017-08-03 |
| EP3407886A1 (en) | 2018-12-05 |
| RU2018128905A3 (enExample) | 2020-03-24 |
| US20210100814A1 (en) | 2021-04-08 |
| US20250268912A1 (en) | 2025-08-28 |
| US10786513B2 (en) | 2020-09-29 |
| US20190134057A1 (en) | 2019-05-09 |
| IL260775B (en) | 2021-09-30 |
| AU2017213154B2 (en) | 2023-02-02 |
| CA3222584A1 (en) | 2017-08-03 |
| US12433898B2 (en) | 2025-10-07 |
| MX2018009252A (es) | 2019-01-21 |
| SG11201806393QA (en) | 2018-08-30 |
| US11529359B2 (en) | 2022-12-20 |
| JP2022088620A (ja) | 2022-06-14 |
| WO2017129801A1 (en) | 2017-08-03 |
| JP2019507736A (ja) | 2019-03-22 |
| CN108697694A (zh) | 2018-10-23 |
| MX388862B (es) | 2025-03-20 |
| JP7115746B2 (ja) | 2022-08-09 |
| AU2017213154A1 (en) | 2018-08-16 |
| CN108697694B (zh) | 2022-12-09 |
| CL2018002023A1 (es) | 2019-02-01 |
| RU2018128905A (ru) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dong et al. | Long-term potentiation decay and memory loss are mediated by AMPAR endocytosis | |
| Moutal et al. | CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide | |
| US12433898B2 (en) | Use of GABAA receptor modulators for treatment of itch | |
| Li et al. | The Atr-Chek1 pathway inhibits axon regeneration in response to Piezo-dependent mechanosensation | |
| Zhou et al. | Lentivirus-mediated klotho up-regulation improves aging-related memory deficits and oxidative stress in senescence-accelerated mouse prone-8 mice | |
| Tao et al. | AMP‐activated protein kinase mediates activity‐dependent axon branching by recruiting mitochondria to axon | |
| Partridge et al. | Conversion of mdx myofibres from dystrophin-negative to-positive by injection of normal myoblasts | |
| KR101554996B1 (ko) | 섬유증을 조절하는 마이크로-ｒｎａ 집단 및 이의 용도 | |
| Shabanzadeh et al. | Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system | |
| Kurasawa et al. | Loss of synaptic ribbons is an early cause in ROS-induced acquired sensorineural hearing loss | |
| Zhu et al. | HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway | |
| CA3061703A1 (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| US20130266663A1 (en) | Sox9 inhibitors | |
| WO2007143630A2 (en) | Treatment of neurofibromatosis with hsp90 inhibitors | |
| Cortez et al. | Disruption of ClC-2 expression is associated with progressive neurodegeneration in aging mice | |
| CN110664815A (zh) | 长春花碱iii在制备预防或治疗阿尔茨海默症药物中的应用 | |
| Liu et al. | Activation of Kv7. 2/3 channels in the PL-NAcc circuit attenuates methamphetamine-associated contextual memory | |
| Barros Ribeiro da Silva et al. | The Rise of Molecules Able to Regenerate the Central Nervous System | |
| RU2781636C2 (ru) | Применение модуляторов gabaa-рецептора для лечения зуда | |
| Shi et al. | A novel role for microtubule affinity‐regulating kinases in neuropathic pain | |
| WO2010087107A1 (ja) | メラノーマの転移抑制剤 | |
| JP6727962B2 (ja) | 癌の予防又は治療剤 | |
| Pham | Influence of Large Conductance Ca2+-and Voltage-Activated K+ Channels (BK) on Synaptic Plasticity in Young and Aged Mice | |
| Marzullo et al. | Distinct Cellular Effects of Myotonic Dystrophy type 2 RAN Tetrapeptides in Drosophila melanogaster | |
| Hamilla | THE ROLE OF THE MECHANICAL ENVIRONMENT ON CANCER CELL TRANSMIGRATION AND MRNA LOCALIZATION |